527 related articles for article (PubMed ID: 26161924)
1. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
2. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
3. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
5. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
6. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
8. Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS; Frenette CT; Keefe SM; Stein SM
Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
10. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T;
Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib: from literature to clinical practice.
Di Marco V; De Vita F; Koskinas J; Semela D; Toniutto P; Verslype C
Ann Oncol; 2013 Apr; 24 Suppl 2():ii30-7. PubMed ID: 23715941
[TBL] [Abstract][Full Text] [Related]
13. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
14. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
16. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Walko CM; Grande C
Semin Oncol; 2014 Feb; 41 Suppl 2():S17-28. PubMed ID: 24576655
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
18. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Zheng SZ; Liu DJ; Sun P; Yu GS; Xu YT; Gong W; Liu J
World J Gastroenterol; 2014 Nov; 20(43):16275-81. PubMed ID: 25473183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
